Using Personal Loans Wisely to Improve Your Money Situation in Singapore

SINGAPORE, June 4, 2026 - (ACN Newswire via SeaPRwire.com) - Managing money in a high-cost city like Singapore can feel complex, especially when multiple financial commitments run in parallel. From education expenses and medical bills to consolidating existing dues, Personal Loans in Singapore are often explored as a flexible financing option. When approached thoughtfully, they can help create breathing room in monthly cash flow and bring more structure to scattered payments. The key lies in understanding how these loans work in the local context and using them in ways that align with income patterns, interest rates, and realistic repayment timelines.Understanding how Personal Loans work in SingaporePersonal Loans in Singapore are unsecured loans, meaning they do not require collateral such as property or fixed deposits. Loan amounts can vary widely depending on income eligibility and lender criteria, subject to applicable regulatory requirements. Interest rates are often quoted as flat rates or effective interest rates (EIR), with EIRs commonly ranging between 2.65% and 3.75% per annum for salaried individuals. Understanding the difference between flat rates and EIRs, as well as how rates vary across lenders, can help borrowers estimate the actual cost of borrowing more accurately. Repayment tenures usually span from one to five years, offering flexibility to match monthly obligations with income cycles.Situations where Personal Loans may help improve cash flowPersonal Loans may be useful in specific scenarios where timing and predictability matter more than long-term borrowing. For instance, consolidating multiple high-interest payments into one structured loan can simplify finances and make monthly outflows easier to track. A consolidated single personal loan instalment per month may feel more manageable than juggling three or four smaller payments with varying due dates. Similarly, planned expenses such as professional certifications or home repairs may benefit from fixed monthly repayments rather than ad-hoc withdrawals from savings. This approach can help maintain liquidity while spreading costs over time.Using Personal Loans for Debt ConsolidationDebt consolidation is one of the more common reasons borrowers explore personal loans in Singapore, especially when dealing with credit card balances. For illustration purpose, credit cards may carry interest rates exceeding 25% per annum, which may strain monthly budgets if balances revolve. A Personal Loan with a materially lower EIR may help reduce the interest burden while providing a clear repayment end date. Over a three-year tenure, consolidating SGD 20,000 in outstanding balances may translate into more predictable instalments and less uncertainty around interest accumulation, depending on the applicable terms. This structured approach may help improve financial clarity without relying on short-term credit cycles.Practical tips to use Personal Loans thoughtfullyAlign the loan amount with a clear purposeBorrowing with a defined goal can help keep loan usage focused and intentional. Whether the aim is consolidating debt or funding a necessary expense, having a specific number in mind can prevent over-borrowing. In Singapore, lenders may offer higher limits based on income, but choosing only what is required can help keep monthly instalments comfortable. This approach may also reduce total interest paid over the loan tenure.Compare EIR, not just headline offersAdvertised rates can sometimes appear attractive, but the EIR provides a clearer picture of the total cost. Processing fees, early repayment charges, and administrative costs can influence the final amount paid. For example, a loan with a 3% flat rate can translate to an EIR closer to 5.5% once fees are factored in. Comparing EIRs across lenders can help identify options that fit better within monthly budgets.Choose a tenure that balances flexibility and affordabilityLonger tenures reduce monthly instalment amounts, but they also increase total interest paid. Shorter tenures may feel heavier on cash flow but can close the loan faster. Borrowers earning between SGD 4,000 and SGD 6,000 per month often opt for a two- to three-year tenure, as it balances instalment size with interest impact. Selecting a tenure that aligns with income stability can help maintain consistency in repayments.Understanding income-based borrowing limitsIn Singapore, borrowing limits for personal loans are typically tied to annual income levels and overall credit assessment. Individuals earning less than SGD 20,000 annually are generally subject to more restrictive unsecured credit caps, while those earning above SGD 30,000 may be eligible for higher unsecured credit limits, subject to the banks' internal credit assessments and applicable regulatory requirements. These guidelines are designed to encourage responsible borrowing without overextending financial capacity. Staying within these limits can help ensure that loan repayments remain proportionate to income, leaving room for savings and everyday expenses. This balance can support longer-term financial resilience rather than short-term relief.Building a healthier money outlook with structured repaymentsOne often overlooked benefit of personal loans is the predictability they bring to monthly planning. Fixed instalments can make it easier to map expenses, set aside savings, and track progress over time. Seeing a loan balance reduce each month steadily may also encourage better financial habits. In Singapore's fast-paced environment, this structure may help individuals stay focused on broader money goals while managing immediate needs. Over time, this clarity may contribute to improved confidence in handling finances.Making Personal Loans work for your financial contextUsing personal loans thoughtfully in Singapore can be a practical way to bring order to complex financial situations. When loan amounts, interest rates, and tenures are aligned with income and clear objectives, they can help improve cash flow and reduce financial stress. Rather than acting as a quick fix, personal loans can serve as a structured tool that supports better financial management. With careful comparison and realistic planning, they may fit into a broader strategy aimed at stability and long-term financial well-being.Disclaimer: This content is published by iQuanti Singapore Pte Ltd, an external marketer engaged and compensated by UOB LtdContact Information:Name: Sonakshi MurzeEmail: Sonakshi.murze@iquanti.comJob Title: ManagerSOURCE: iQuanti Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

GR Premiers GRMN Corolla

Toyota City, Japan, June 4, 2026 - (JCN Newswire via SeaPRwire.com) - GAZOO Racing (GR) held the world premiere today of the GRMN Corolla―the ultimate GR Corolla, engineered to deliver a confident, full-throttle experience on Germany's Nürburgring racetrack, the starting point for both GR, which is committed to building ever-better motorsports-bred cars, and Toyota Master Driver Morizo. The GRMN Corolla represents a comprehensive honing of the GR Corolla ignited by Morizo's strong desire to "bring back a Corolla that captivates our customers".The GRMN Corolla is to be available in limited quantities, primarily in Japan, North America, and Australia. In Japan, plans are to accept sales negotiations requests via the "GR app" smartphone app from around autumn 2026, with sales scheduled to begin in 2027. The new model is now on display at the Fuji Motorsports Forest Welcome Center until June 28.*1GRMN Corolla (prototype in Black Gravite)The GRMN Corolla, as the ultimate GR Corolla, enables a high level of car-driver unity even when pushing the limits.Its increased engine torque aims to unleash greater untamed energy.It features exclusively designed aerodynamic performance parts and a suspension honed through competing in the Super Taikyu Series and testing at the Nürburgring.Its 4WD control was optimized through repeated testing at the Nürburgring.The cockpit is equipped with a custom-designed driver's seat and a brush-metal instrument panel and has been evolved for enabling the driver to focus more fully on driving.In addition to the 2-seater GRMN Corolla, a 5-seater MORIZO RR version equipped with the GAZOO Racing Direct Automatic Transmission is currently being developed.Aiming for a car that can attack the Nürburgring at full throttleSpurred by the stance of Toyota Motor Corporation Chairman and Master Driver Akio Toyoda, a.k.a. Morizo, of: "If it's going to bear the GRMN name, it needs to be a car that can duly handle the Nürburgring", the development team honed the GRMN Corolla on what is said to be the world's most grueling race course. Going all out on the Nürburgring, which provides road inputs and surface variations not found on regular test courses, highlights a car's weaknesses. Developing the GRMN Corolla at the Nürburgring enabled crafting a car that can be controlled at will at all speeds, even on rough surfaces.In addition to development through track testing at the Nürburgring, the GRMN Corolla also went through its paces in Japan's Super Taikyu Series. It was also methodically validated using advanced driving simulators. But it was driving it at the Nürburgring that brought unexpected challenges to the fore. The development team overcame those challenges one by one in pursuit of achieving a high level of car-driver unity, enabling the car and driver to remain in constant, effective communication even when pushing the limits.GR has applied the insights gained from GRMN Corolla development to the evolution of the base GR Corolla. For the 2026 GR Corolla, announced in September 2025 and launched in November of that year, the application of structural adhesive was extended by 13.9 meters to 32.7 meters to reinforce the body structure, and an added cool-air duct reduces the rise in intake air temperature during high-load driving. Both were the result of applying lessons learned at the Nürburgring.GRMN Corolla main featuresAerodynamic performance: Super Taikyu Series-tested and Nürburgring-honedIn Super Taikyu Series and similar races and at the Nürburgring, cars constantly travel at high speeds and experience high g-forces. Maximizing vehicle performance under these conditions crucially requires that all four wheels maintain firm contact with the road. The GRMN Corolla features exclusively developed aerodynamic performance parts for enhanced road holding. Its hood duct, fender ducts, front side spoilers, and rear wing incorporate know-how gained from racing, tested on the hydrogen engine-powered GR Corolla that competes in the Super Taikyu Series. Based on all-inclusive Super Taikyu Series trial and error, fine-tuning came at the Nürburgring. This effort included adjusting the rear wing angle, which features a five-step adjustment mechanism, in 1-degree increments during driving tests with professional drivers to verify effectiveness and determine the optimal specification.Exclusive suspension fine-tuned through extensive Nürburgring testingThe GRMN Corolla's suspension employs exclusive front and rear monotube shock absorbers with rebound springs for improved inner-wheel traction during cornering and for enhanced high-speed cornering performance.The Nürburgring road surface includes environments that induce significant vertical suspension travel beyond that experienced on typical circuits. To ensure high stability for confident driving even in such conditions, extensive Nürburgring test runs facilitated optimization of bump-stop characteristics. The exclusive shock absorbers were developed by adjusting their stroke down to a millimeter at the front and rear for optimal balance. Furthermore, for enhanced cornering stability and braking performance, the GRMN Corolla sports 245/40ZR18 "Michelin Pilot Sport Cup 2" high-grip tires, which are 10 mm wider than those on the base vehicle.The control program of the GRMN Corolla's EPS (electric power steering) has been modified from that on the base vehicle to generate the required amount of assistance torque even during cornering under high g-forces. The exclusively tuned 4WD control system provides optimal rear torque distribution during straight-line driving and enhanced stability at the onset of steering input at extremely high speeds.Internal combustion engine evolution via the hydrogen engine-powered CorollaGR has been gaining valuable lessons for the evolution of the internal combustion engine by competing in the Super Taikyu Series with a hydrogen engine-powered GR Corolla, as extended, high-load endurance racing helps heighten not only the potential of hydrogen technology but also that of fundamental internal combustion engine components. Applying insights gained from competing in the Super Taikyu Series has enabled the GRMN Corolla to achieve a maximum engine torque of 415 Nm*2, 15 Nm greater than that of the base vehicle. The development team optimized the GRMN Corolla's engine characteristics by analyzing the range of engine use during circuit driving, focusing on increasing torque in the 3,600-4,800 rpm mid-speed range, which is crucial for accelerating out of corners. To maintain stable, high engine output even during continuous full-throttle driving, the GRMN Corolla comes with an intercooler spray system, in addition to the cool-air duct added to the 2026 GR Corolla.Also, in pursuit of an even higher level of performance and an "untamed energy that captivates customers", the GRMN Corolla has no rear seats as part of an effort to achieve thorough weight reduction. The power-to-weight ratio has been improved by reducing weight by 30 kilograms compared to the base vehicle*3, providing customers with an unparalleled driving experience.A cockpit designed to unlock an even higher level of performanceThe GRMN Corolla boasts not only exclusively tuned driving performance but also a specially designed cockpit featuring a driver's seat and an instrument panel meticulously crafted to enable customers to unlock the value of genuine driving performance. The custom-designed full bucket driver's seat*4 was based on the driving position in Super Taikyu Series race cars to achieve holding performance capable of withstanding higher lateral g-forces. The carefully adjusted seat length facilitates clutch operation, and the seat's glass fiber-reinforced polymer (GFRP) construction helps reduce weight. In addition to safety being first and foremost, the aim was to create a driver's seat that enhances car-driver unity while considering everyday ease of ingress and egress. Development involved installing the seat in a car competing in the Super Taikyu Series and incorporating feedback from various professional drivers, including that from evaluations conducted while wearing a helmet.The cockpit's design and meticulously considered color scheme create a space that enables the driver to focus more fully on driving and features an exclusive flocked instrument panel and flocked front pillars. Carbon-fiber ornamentation―developed and manufactured by the Carbon Section at Toyota Motor Corporation's Motomachi Plant―adorns the instrument panel on the passenger side. Other special items include instrument panel padding bearing Morizo's signature, door trim and shift knob accented in Alumite Red, and a GRMN-exclusive serial number plate. GR Corolla MORIZO RR (concept model)Currently under development is the GR Corolla MORIZO RR, an ultimate 5-seater model of the GR Corolla equipped with the GAZOO Racing Direct Automatic Transmission, for which the unveiling and launch dates have yet to be determined. The GR Corolla MORIZO RR is now on display as a concept model alongside the GRMN Corolla at the Fuji Motorsports Forest Welcome Center until June 28.*1*1 Please check the Fuji Motorsports Forest website (https://en.fujimotorsportsforest.jp/) for information on closed days and public opening hours during the exhibition period.*2 415 Nm is the maximum engine torque for the Japan-specification model*3 Maximum engine torque and vehicle weight vary by market.*4 Only in Japan and Australia; semi-bucket seats in North AmericaToyota Motor Corporation works to develop and manufacture innovative, safe and high-quality products and services that create happiness by providing mobility for all. We believe that true achievement comes from supporting our customers, partners, employees, and the communities in which we operate. Since our founding over 80 years ago in 1937, we have applied our Guiding Principles in pursuit of a safer, greener and more inclusive society. Today, as we transform into a mobility company developing connected, automated, shared and electrified technologies, we also remain true to our Guiding Principles and many of the United Nations' Sustainable Development Goals to help realize an ever-better world, where everyone is free to move.SDGs Initiatives: https://global.toyota/en/sustainability/sdgs/  Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

雲頂新耀與天廣實達成倍捷欣(R)商業化授權許可協議 深化亞太創新藥市場佈局

香港, 2026年6月4日 - (亞太商訊 via SeaPRwire.com) - 雲頂新耀(HKEX 1952.HK)宣布與北京天廣實生物技術股份有限公司(以下簡稱“天廣實”)達成商業化授權許可合作協議,獲得倍捷欣(R)(MIL62,通用名:奧妥珠單抗β注射液)在亞太地區(東南亞、印度、韓國、澳大利亞、新西蘭、中國香港、中國澳門及中國臺灣地區)的臨床開發及商業化權益。根據相關協議,雲頂新耀將向天廣實支付人民幣2,300萬元的首付款,以及最高不超過人民幣1.86億元的銷售里程碑款。天廣實可獲得該產品在亞太地區的銷售毛利額分成款項。此次合作將進一步強化雲頂新耀在腎科及自身免疫疾病等領域的亞太市場布局,並與現有腎科管線形成協同效應。雲頂新耀將依託已獲驗證的臨床開發及商業化能力,加速推動倍捷欣(R)的市場准入與商業化進程,持續釋放亞太區域的增長潛力,並推進公司在全球創新藥市場的長期戰略發展。倍捷欣(R)是天廣實自主研發的創新型第三代CD20抗體藥物。根據相關資料顯示,該藥物已於2026年2月在中國獲批上市,用於治療視神經脊髓炎譜系疾病(NMOSD),成為全球首款治療該疾病的CD20抗體,也是中國在該領域的首款國產藥物。倍捷欣(R)用於治療原發性膜性腎病(PMN)的新藥上市申請亦處於中國國家藥監局的「優先審評審批」階段,有望成為全球首款獲批的PMN特效藥物。此外,倍捷欣(R)正在進行的臨床III期試驗覆蓋系統性紅斑狼瘡(SLE)以及濾泡性淋巴瘤(FL)多個治療領域,並具備向其他自身免疫性疾病持續拓展的潛力。雲頂新耀董事會主席吳以芳表示:「我們非常高興能與天廣實就倍捷欣(R)達成此次合作。倍捷欣(R)不僅是全球首款獲批治療NMOSD的CD20抗體,也是一款具有差異化優勢和廣闊市場前景的創新藥,在腎科及自身免疫疾病領域展現出顯著的臨床潛力。此次合作將進一步豐富雲頂新耀在腎科及自身免疫領域的產品布局,並與現有管線形成良好的協同效應。依託公司已建立並持續強化的臨床開發及商業化能力,我們有信心加速推進倍捷欣(R)在亞太地區的開發與商業化進程,推動其儘快惠及更多患者,讓創新療法更快轉化為臨床可及性,並進一步提升公司在亞太及全球創新藥市場的影響力。」天廣實總裁陳魯寧表示:「我們非常欣喜與雲頂新耀達成倍捷欣(R)在亞太地區的合作。倍捷欣(R)作為全球首款獲批治療NMOSD的CD20靶向藥物,也是潛在全球首款治療PMN的特效藥物,擁有非常出色的產品競爭力與市場潛力。自產品上市以來,倍捷欣(R)在中國大陸地區已經取得了優異的商業化成績,此次合作將進一步強化倍捷欣(R)在整個亞太市場的商業化網路與品牌影響力,為中國大陸以外的更多腎科及自身免疫性疾病患者帶來「欣」希望。」倍捷欣(R)目前已在腎科及多個自身免疫疾病領域展現出顯著的臨床及治療價值,並具備廣闊的適應症拓展潛力。其在NMOSD、PMN及SLE等疾病領域的持續布局與進展,有望為患者帶來更多創新治療選擇。NMOSD是一種高復發率、高致殘率的中樞神經系統自身免疫性疾病,多發於青壯年女性。該病通常為急性或亞急性起病,可迅速進展,約90%的患者在三年內經歷復發,嚴重者可導致失明甚至癱瘓。倍捷欣(R)在單藥治療中顯示出降低復發風險的顯著優勢,並在療效數據中展現出優異表現,凸顯其作為單藥療法的臨床價值與治療便利性。PMN是成人腎病最常見的病理類型,約30%-40% 的患者在5-15年內可能進展為終末期腎病。目前全球範圍內尚無獲批的特效藥。臨床III期研究顯示,倍捷欣(R)單藥治療在臨床完全緩解、免疫學完全緩解及臨床緩解等各項指標上均展現出顯著優勢。此外,倍捷欣(R)具有良好的安全性和耐受性,並且給藥週期便捷,患者初始治療後,每六個月僅需進行一次靜脈注射,可顯著降低治療負擔,同時有助於提升長期依從性。SLE是一種慢性系統性自身免疫疾病,倍捷欣(R)目前處於臨床III期研究階段,具有24–28周的長給藥間隔優勢,可滿足患者對長效治療方案的臨床需求,有望為SLE患者提供更優治療選擇。此次合作被視為雲頂新耀提升腎科及自身免疫領域戰略縱深的重要舉措。隨著倍捷欣(R)在PMN等適應症上的開發與商業化推進,公司腎科產品矩陣將得到進一步補充,並強化現有管線的協同效應。此外,業內普遍認為,未來數年中國創新藥加速進入亞太市場將迎來重要發展機遇。憑藉臨床價值、可負擔性及可及性方面的綜合優勢,中國創新藥與亞太地區日益增長的醫療需求持續契合。雲頂新耀近年來持續推進亞太區域戰略布局,已逐步形成覆蓋臨床開發、市場准入及商業化運營的能力體系。通過引入倍捷欣(R)等具備差異化臨床價值的創新產品,雲頂新耀正進一步拓展區域產品組合及市場覆蓋,推動公司腎科及自身免疫領域商業化價值的釋放,並為亞太業務發展注入新的增長動能。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Everest Medicines Enters Commercialization License Agreement with Mabworks for Bejescin(R) in the Asia-Pacific Market

HONG KONG, Jun 4, 2026 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK) announced that it has entered into a commercialization license agreement with Beijing Mabworks Biotech Co., Ltd. (“Mabworks”), under which the Company has obtained exclusive rights for the clinical development and commercialization of Bejescin(R) (MIL62, Obinutuzumab beta Injection) across the Asia-Pacific region, including Southeast Asia, India, South Korea, Australia, New Zealand, Hong Kong SAR, Macao SAR, and Taiwan region, China. Under the terms of the agreement, Everest Medicines will pay Mabworks an upfront payment of RMB 23 million and sales milestone payments of up to RMB 186 million. Mabworks will also be eligible to receive a share of gross profit in the region.This collaboration will strengthen Everest Medicines’ presence in nephrology and autoimmune diseases across the Asia-Pacific region, creating synergies with its nephrology portfolio. Leveraging its established and proven clinical development and commercialization capabilities, the company aims to advance the development of Bejescin(R) and support its launch in the Asia-Pacific region, while furthering its long-term strategy in the global innovative medicines market.Bejescin(R) (MIL62, Obinutuzumab beta Injection) is a novel third-generation anti-CD20 monoclonal antibody. As shown in relevant sources, it was approved in China in February 2026 for the treatment of neuromyelitis optica spectrum disorder (NMOSD), becoming the first CD20 antibody approved for this indication globally and the first domestically developed therapy in China. The New Drug Application (NDA) for primary membranous nephropathy (PMN) is currently under Priority Review by the National Medical Products Administration (NMPA), with the potential to become the first approved targeted therapy for PMN worldwide. Bejescin(R) is also in Phase III trials for systemic lupus erythematosus (SLE) and follicular lymphoma (FL), with potential for further expansion into other autoimmune indications.“We are delighted to collaborate with Mabworks on Bejescin(R). As the first CD20 antibody approved globally for NMOSD, Bejescin(R) has demonstrated strong clinical potential and significant opportunities in nephrology and autoimmune diseases,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “This collaboration strengthens Everest’s portfolio in these therapeutic areas and complements our existing pipeline. With our expertise in clinical development and commercialization, we are confident in advancing Bejescin(R) across the Asia-Pacific region, bringing this innovative therapy to more patients and improving access. At the same time, we are committed to further strengthening Everest Medicines’ presence in the Asia-Pacific and global innovative medicines market.”“We are thrilled to announce our partnership with Everest Medicines on Bejescin(R) across the Asia-Pacific region. As the first approved CD20-targeted therapy for NMOSD worldwide and the potential global first targeted therapy for PMN, Bejescin(R) possesses exceptional product competitiveness and market potential.” said Mr. Luning Chen, President of Mabworks. “Since its launch in Mainland China, Bejescin(R) has achieved outstanding commercial performance. This collaboration will further strengthen Bejescin(R)’s commercial network and brand influence across the Asia-Pacific region, bringing ‘New Hope’ to more patients with renal and autoimmune diseases.”Bejescin(R) has shown meaningful clinical and therapeutic benefits across nephrology and multiple autoimmune disease areas, with potential for further indication expansion. Its development in NMOSD, PMN, and SLE is expected to provide more innovative treatment options for patients.NMOSD is a debilitating autoimmune disorder targeting the central nervous system characterized by high recurrence and disability rates, predominantly affecting young and middle-aged women. The disease typically presents acute or subacute onset and can progress rapidly, with approximately 90% of patients relapsing within three years. Severe cases may result in blindness or paralysis. Bejescin(R) has demonstrated a significant reduction in relapse risk as a monotherapy, with strong efficacy data underscoring both its clinical value and the convenience.PMN is one of the most common pathological types of adult nephropathy, with approximately 30%-40% of patients progressing to end-stage renal disease (ESRD) within 5 to 15 years. Globally, there are no approved targeted therapies for PMN. Phase III clinical data demonstrated that Bejescin(R) monotherapy provides significant advantages across multiple efficacy endpoints including complete clinical remission, complete immunological remission and overall clinical remission. Furthermore, Bejescin(R) showed a favorable safety and tolerability profile, together with a convenient dosing regimen. Following initial treatment, patients require only one intravenous infusion every six months, reducing treatment burden and supporting long-term treatment adherence.SLE is a chronic, systemic autoimmune disease that primarily affects young women. For this indication, Bejescin(R) is in Phase III clinical trial and offers the potential for administration every 24 to 28 weeks, addressing the need for long-acting therapies and providing an improved treatment option for patients with SLE.This collaboration is regarded as an important strategic step for Everest Medicines to deepen its footprint in the nephrology and autoimmune disease areas. With the development and commercialization of Bejescin(R) in indications such as PMN, the company’s nephrology product portfolio will be further strengthened, enhancing the synergistic effects within its existing pipeline.In addition, there is a broad consensus in the industry that the coming years may represent an important window of opportunity for the accelerated adoption of innovative Chinese medicines into the Asia Pacific region. Chinese innovation is becoming increasingly competitive in clinical value, affordability and accessibility, with growing alignment to the needs of healthcare systems and patients across the region. In recent years, Everest Medicines has continuously advanced its regional strategy in Asia-Pacific, gradually building an integrated capability system covering clinical development, market access, and commercialization. By introducing innovative products with differentiated clinical value such as Bejescin(R), the company is further expanding its regional product portfolio and market coverage, realizing the commercial value of its nephrology and autoimmune disease businesses, and injecting new growth momentum into its Asia-Pacific operations. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

把足球戰略搬進電信業 BT CEO重造英國數碼未來的賭注

(SeaPRwire) -   大眾對電信基礎建設的印象,永遠是出事才會想起。斷網、沒訊號才會罵幾句,平常根本不會注意這塊業務。英國電信集團BT的現任CEO艾莉森・柯克比,不想讓BT繼續當背後的透明人。她今年登上全球最具影響力女性榜,排名第66位,正用足球邏輯改造BT,也衝擊英國整體數碼產業格局。 柯克比2024年2月接手BT後,已經帶動公司股價翻倍。BT公布的2026財年稅前利潤,大約落在19億美元。她手上握有四個品牌,分別是BT、EE、Plusnet和Openreach。過去幾年BT砸了250億英鎊,鋪設光纖和移動網絡,大部分資源都傾斜給EE。BT品牌和企業業務的投資長期不足,這是她要優先解決的問題。 柯克比把自己定位成足球領隊,外界開玩笑說她是電信界的加雷斯・索斯蓋特,她自認更像亞歷克斯・弗格森爵士。她說網絡基礎建設是球隊的防守,現在已經夠紮實。現在球隊缺的是能進球的前鋒,要多加投資BT品牌和企業業務,才能把過去鋪網的投資轉成實質獲利。她還和歐足聯等頂級賽事合作,展現BT網絡的穩定度。 柯克比認為,英國數碼基礎建設過去太強調競爭,投資誘因不足,導致市場過度碎片化。太多業者一起經營,反而帶來網絡韌性風險,拖慢整體產業升級速度。她說全球數碼基礎建設做得好的國家,光纖和移動領域大約都維持三家關鍵業者,英國長遠來看也得走向這個結構。 BT不只追求企業獲利,還要承擔國家關鍵基礎建設的責任。英國預定2027年1月全面關閉傳統固話網絡,BT要協助依賴固話的社區民眾,學習新的數碼技能,從網路銀行到預約就診都要重新適應。柯克比也遊說整個產業團結,爭取合理的投資報酬,推動市場結構調整。 這場足球主導的改革,會讓英國電信市場版圖在三年內迎來大洗牌。本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈,覆蓋超過6,500個媒體庫、86,000名編輯和記者,以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。

赤子城科技註銷逾517萬股回購股份,累計金額超4,500萬港元

EQS via SeaPRwire.com / 2026-06-04 / 19:30 UTC+8   [2026年6月4日 – 香港] 領先的全球化社交娛樂公司 – 赤子城科技有限公司(「赤子城科技」或「本公司」,股份代號:9911;連同其附屬公司統稱「本集團」)發佈公告稱,公司已註銷此前於2026年4月27日至5月29日期間購回的合共517.4萬股股份,涉及總回購金額約4,532萬港元。   此前,赤子城科技於2026年3月宣佈,計畫未來兩年斥資約3億港元在市場上進行股份回購。公告顯示,本次註銷後,赤子城科技已發行股份總數將由14.13208391億股減少至14.08034391億股,公司不再持有任何庫存股份。   赤子城科技董事會表示,註銷購回股份將提高每股股份資產淨值及每股股份盈利,符合公司及股東整體利益,董事會將繼續不時檢討及全權酌情決定進行股份購回。公司近期已連續推進回購及註銷動作,向市場釋放出管理層對公司長期發展前景的信心,也體現出其對股東回報和資本效率的重視。   自今年3月納入港股通以來,赤子城科技累計成交額大幅提升,南向資金參與熱情持續升溫。從回購時點看,此輪回購正值公司一季報發佈後。4月22日,赤子城科技披露2026 年第一季度未經審核營運資料,期內總收入預期約人民幣20.30至21.30億元,同比增長約33.0%至39.6%。其中,核心社交業務同比增長約31.3%至37.2%;創新業務同比增長約46.7%至58.7%,主要得益於AI驅動下短劇業務的快速增長。   有關赤子城科技 赤子城科技是一家全球化的互聯網公司,2019年在港交所主板上市,股票代碼為09911.HK。公司以「創造美好情緒價值」為願景,在社交、遊戲等領域打造了數十款面向全球用戶的APP,包括泛人群社交產品 MICO、YoHo、TopTop、SUGO;多元人群社交產品 HeeSay;精品遊戲產品 Alice's Dream: Merge Games等,累計服務過上百個國家和地區的超過10億全球用戶。赤子城科技深耕中東北非市場,並積極佈局東南亞、歐美、日韓等地區,致力於成為全球最大的社交娛樂公司。   如欲查詢更多資訊,請聯絡: DLK Advisory  pr@dlkadvisory.com    2026-06-04 此財經新聞稿由EQS via SeaPRwire.com轉載。本公告內容由發行人全權負責。瀏覽原文: http://www.todayir.com/tc/index.php

SeaPRwire 打通印泰越主流媒體生態

Hong Kong - 2026年6月3日 - (SeaPRwire) - 東南亞正在成為全球經濟增長的新引擎,而印尼、泰國和越南則是其中最耀眼的“活力三駕馬車”。為了助力全球企業搶佔東南亞市場紅利,知名媒體服務商 SeaPRwire 今日宣佈,已成功深度打通印尼、泰國和越南三國的本地主流媒體生態,為出海企業構建了直達東南亞億級消費者的公關綠色通道。 印尼的人口紅利、泰國的消費活力以及越南的製造與科技崛起,讓這三個國家成為各行各業出海的必爭之地。然而,東南亞地區語言多樣、媒體形態分散,且各國的宗教文化背景迥異,這給外來品牌的公關傳播帶來了極大的挑戰。SeaPRwire 此次深入本土的拓展,正是為了解決這一痛點。 在印尼,SeaPRwire 強化了與雅加達主流印尼語門戶及高流量社交媒體矩陣的合作;在泰國,平臺無縫對接了曼谷核心的泰語財經與時尚生活類媒體;在越南,則重點佈局了河內與胡志明市的科技、創投以及年輕一代高度依賴的數字媒體。通過這種精細化的本土媒體下沉,SeaPRwire 確保企業的資訊能夠準確、無損地傳達給當地最具消費力的群體。 “開拓東南亞市場,‘接地氣’是第一要素,”SeaPRwire 的東南亞市場總監表示,“我們不僅僅是把英文稿件翻譯成當地語言,更是深入到印泰越三國的媒體生態毛細血管中。我們希望用最符合當地語境的新聞敘事,幫助企業建立起有溫度、有信任度的本土品牌形象。” 關於SeaPRwire SeaPRwire 是亞洲領先的 AI 驅動型贏取媒體(Earned Media)傳播管理平臺,專為公關及傳播專業人士打造。通過其旗艦專案 Branding-Insight,平臺無縫連接超過 8 萬名記者、編輯,以及坐擁 3 億粉絲的 KOL 矩陣。借助先進的 AI 技術,SeaPRwire 幫助用戶精准鎖定媒體目標、定制個性化推介,並全面衡量亞太核心市場(包括日、韓、中及東南亞)的公關傳播效果。 媒體聯絡 公司: SeaPRwire 聯絡: Media team 郵箱: cs@seaprwire.com 網站: https://seaprwire.com

當你恐慌拋售時,Musk 正悄悄發放 37.5 億美元紅利

(SeaPRwire) -全球科技股正在遭遇拋售。交易員們紛紛套現離場。Ray Dalio 直言 AI 是泡沫。這種焦慮在蔓延。但 Silicon Valley 的核心卻異常冷靜。Elon Musk 正在籌劃一場巨額分配。這是 37.5 億美元的內部人紅利。市場在恐懼,他在分錢。這種反差極其刺眼。 SpaceX 的 IPO 計劃中埋藏著關鍵線索。那裡暗示了與 Tesla 合併的可能性。更重要的是內部人士的收益。Elon Musk 準備給 SpaceX 內部人員帶來 37.5 億美元的意外之財。這些資金將流向朋友和家人。與此同時,明天的就業報告即將出爐。聯準會可能被迫加息。這些冰冷的事實擺在桌上。 這本質上是一場流動性盛宴。在公開市場估值動搖前鎖定價值。Tesla 合併的線索暗示了更大的資本棋局。這是為了構建資本護城河。無論 AI 是否真的是泡沫,這筆錢已經落袋為安。最終的行業終局很清晰。資本正在向核心極權收縮。外界的恐慌只是背景音。本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈,覆蓋超過6,500個媒體庫、86,000名編輯和記者,以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。

Hymson Highlights Operational Reliability at The Battery Show Europe 2026

EQS Newswire / 03/06/2026 / 11:12 UTC+8 From Cell to System. From proven manufacturing experience to localized European support. Not only broad technology coverage, but the operational stability you can depend on. June 9–11, 2026 | Booth 1-B30 European battery manufacturers are moving beyond equipment procurement toward industrial ramp-up, where yield, uptime, process discipline, and local service capability determine long-term competitiveness. As battery manufacturing moves from pilot validation toward industrial-scale production, operational reliability is becoming increasingly critical across the industry. At The Battery Show Europe 2026, Hymson returns for its fifth consecutive year with a clear message for the European market: “How we make it reliable.” From process validation to mass production. Battery industrialization is not only about installing equipment. It requires process validation, operator training, spare parts readiness, data visibility, and continuous improvement mechanisms. Over the past five years, Hymson has continued to deepen its engagement with the European market, working alongside battery manufacturers amid evolving production demands, technology transitions, and industrial-scaling challenges. This long-term collaboration has enabled Hymson to continuously refine both its technologies and manufacturing methodologies for global battery production environments. Behind this commitment is sustained investment in innovation and engineering capability. By 2025, Hymson’s cumulative R&D investment will reach USD 86 million, with 34.47% of employees dedicated to R&D. Total operating revenue is projected to reach USD 939 million in 2026, supporting continued advancement in next-generation battery manufacturing technologies and industrial delivery capability. Mid-Section Turnkey Solutions for Scalable Manufacturing At Booth 1-B30, Hymson will present its latest Mid-Section Turnkey Solution through a comprehensive product matrix and a series of scaled technology models showcasing key manufacturing innovations, alongside extensive battery process samples demonstrating end-to-end manufacturing capabilities. The scaled equipment models on display include: Solid-State Dry-Electrode Solution Film-Forming & Calendering & Lamination Integrated Machine  390 High-Speed Cutting & Stacking Machine CT Inspection Machine for Prismatic Assembly Through these scaled technology models, Hymson will provide visitors with a more intuitive understanding of process integration, equipment architecture, and manufacturing workflow within next-generation battery production environments. Hymson will also showcase: 588Ah Cell Samples Developed for Overseas Customer Requirements 588Ah Cell Cap & Can Laser Welding Samples 40+ process samples covering electrode manufacturing, surface treatment, prismatic assembly, and stacking technologies Together, these exhibits reflect Hymson’s integrated approach to mid-section manufacturing — combining process capability, operational consistency, and scalable production performance. Reliability Starts from Cell Design For Hymson, manufacturing reliability does not begin at equipment installation or even at mass production. It begins much earlier — at the cell design and manufacturability assessment stage. To support customers throughout the entire industrialization journey, Hymson provides an integrated consulting and engineering support framework covering: Cell Design to Manufacturing Production Line Planning Mass Production Line Ramp-up Support Training A key focus within this framework is manufacturability validation before mass production. For many next-generation battery technologies, laboratory-level performance alone is not sufficient for successful industrialization. To reduce scaling risks, Hymson provides DOE (Design of Experiments) and DTM-based battery process analysis to support parameter optimization, blueprint evaluation, and manufacturability feasibility study. Through this process, Hymson helps customers establish: Optimized Process Parameters Manufacturable Battery Analysis Stable Transition from Validation to Mass Production Reduced Ramp-Up Uncertainty and Operational Risks Hymson helps customers translate validated pilot-line conditions into scalable mass-production workflows with thousands of successful delivery and implementation experiences as lessons learned, transitioning into Know-How for the customers, enabling smoother and more accurate alignment between pilot validation and large-scale production environments. This approach helps minimize the risks of industrialization while accelerating mass-production readiness. Technical discussions and in-depth solution exchanges will be available throughout the exhibition. Digitalized Operations for Long-Term Stability Beyond manufacturing equipment, Hymson will also present its End-to-End intelligent manufacturing support across equipment, logistics, and operations management This includes Hymson’s intelligent warehousing & logistics solution together with the IEMS intelligent equipment operation and maintenance system. Driven by AI algorithms and 3D visual monitoring technologies, the system enables: Digital Closed-Loop Production Real-Time Operational Visibility Intelligent Equipment Maintenance Data-Driven Production Management Dark-Factory-Oriented Operation Scenarios The system supports higher levels of automation and unmanned operation where applicable by integrating manufacturing execution, logistics coordination, and equipment operation into a unified system, Hymson helps customers improve operational transparency, production efficiency, and long-term factory stability. Spare Parts Support Built Around Operational Continuity To further strengthen production reliability, Hymson continues to enhance its global spare parts service capability. Hymson provides both original Hymson spare parts and third-party qualified industrial spare parts, tailored to customer requirements, supported by flexible supply mechanisms and predictive inventory planning. The service framework helps customers secure: Critical Spare Parts Availability Improved Price and Lead-Time Predictability Reduced Downtime Risks Lower Inventory Burden Where Applicable Optimized Total Cost of Ownership (TCO) Through data-driven spare parts forecasting and scheduled replenishment systems, Hymson aims to establish a replicable, stable after-sales support structure for long-term manufacturing operations. Advancing Reliable Battery Manufacturing from Asia to Europe Returning to The Battery Show Europe 2026 for the fifth consecutive year reflects Hymson’s long-term commitment to supporting Europe’s battery manufacturing ecosystem. From process development to intelligent factory operations, Hymson continues to combine large-scale manufacturing experience from Asia with localized industrial collaboration in Europe — helping battery manufacturers build production systems designed not only for technological advancement but also for reliable long-term operation. As Hymson has always stated, visitors are invited to discuss specific challenges such as process validation, ramp-up risk reduction, equipment OEE improvement, spare parts planning, and localized service support. Company: Hymson Laser Technology Group Co., Ltd. Contact Person:  liruiyu Email: liruiyu@hymson.com Website:  https://www.hymson.com 03/06/2026 Dissemination of a Financial Press Release, transmitted by EQS News. The issuer is solely responsible for the content of this announcement. Media archive at www.todayir.com View original content: EQS News

線下調研紀要:實探現代牙科(03600.HK)東莞基地 高瓴加持下的全球義齒龍頭如何再成長?

香港, 2026年6月4日 - (亞太商訊 via SeaPRwire.com) - 今年,高瓴資本以每股5.8港元、溢價12%的代價一舉拿下現代牙科1.61億股,躍升為第二大股東。市場一度好奇:這究竟是財務投資,還是對全球義齒龍頭價值的重倉押注?帶著這個疑問,我們走進了現代牙科位於東莞松山湖的全球核心生產基地,試圖從產業邏輯出發,梳理2026年公司必須關注的幾大核心亮點。(現代牙科東莞基地調研相關影像資料)數碼化滲透加速,行業拉開結構性重塑大幕全球義齒行業正處於從"手工作坊"向"數碼化智造"轉型的關鍵拐點。當前口內掃描器在牙醫端的普及率僅15%-25%,仍屬早期滲透階段。隨著設備降價和教學體系更新,未來幾年將進入加速普及期。數碼化帶來的變化是顛覆性的:-交付週期從傳統9-11天壓縮到7天以內;-返工率從行業平均6%-8%銳減至1%-2%;-數碼化能力正成為牙醫選擇供應商的首要決策變數。據美國牙科技工所協會數據,美國牙科實驗室65%的銷售來自單人執業的牙醫診所,這些機構普遍缺乏對數碼化轉型的認知。而現代牙科作為全球義齒行業數碼化先鋒,正成為這廣闊市場的革新者,加速市場教育的同時也在不斷提升自身佔有率。行業數碼化轉型大勢所趨,現代牙科將充分受益行業轉型紅利。集中生產+自有分銷,鑄就全球化雙輪驅動壁壘現代牙科的核心競爭模式可概括為"低成本國家集中生產、高附加值市場全球分銷"。公司在東莞、越南、泰國等地建立了多個集中化生產基地,不僅有效分散地緣政治風險,也為未來3-5年儲備了充裕的產能擴張空間。東莞基地2024年完成深圳產能整合,運營效率顯著提升;越南工廠進入成熟期;泰國Hexa Ceram市占率超28%,成為輻射東南亞的重要支點。更關鍵的是,公司通過近十年的並購整合,搭建起覆蓋全球的自有獨家分銷網路。旗下Elysee、Labocast、洋紫荊等本地化品牌,配合集中生產模式,帶來了更高的定價權與客戶粘性,這是許多代工廠難以逾越的護城河。從代工到方案設計,數碼化升維賦能牙醫現代牙科已悄然完成角色躍遷——從被動接單的加工廠,轉型為主動為牙醫賦能的"數碼化解決方案提供商"。通過整合口內掃描、面部掃描、CBCT等多源醫療數據,公司能直接為牙醫輸出治療方案設計、笑容模擬、治療前後對比,從而將自身價值從"產品供應"升級為"診所營收增長的催化劑"。這一能力顯著提升了高單價療程(如種植、貼面、矯正)的轉化率,並深化了牙醫對公司的依賴。同時,基於40年複雜案例資料庫推進的"混合療程+交叉銷售"戰略,將義齒修復與旗下自研透明矯治器TrioClear、牙齒美容貼面等打包為整體笑容設計服務。2025年,TrioClear已實現收益5,970萬港元,兩年複合增長率達33.2%,驗證了品牌力和管道協同效應。門檻抬高、長尾出清,全球複製能力加速收割數碼化義齒製造對資本、設備、軟體、數據處理和技師培訓提出了極高要求,涵蓋口內掃描檔案處理、CAD/CAM、3D打印、三維成像等數碼化技術,實現從數據採集、診斷設計到協助醫生治療實施的全流程數碼化。這正在系統性地擠走缺乏資金和技術的小型技工所,釋放出大量市場份額。現代牙科憑藉規模效應和資金優勢,正被動兼主動收割這些份額。與此同時,公司覆蓋全球的銷售網絡和牙科智庫生態,賦予了其罕見的"從1到100"的複製能力。任何在單一市場驗證成功的創新方案(如TrioClear),均可通過自有管道迅速導入歐美、澳洲、大中華等其他市場。這種全球推廣效率,是區域性廠商根本難以望其項背的。強化醫療數據處理能力,成為AI時代的口腔數據巨頭公司每年處理近300萬宗修復案例,積累的是一份海量、多源、高標注品質的口腔醫療數據資產。在AI大模型重塑各行各業的當下,這一數據金礦的價值愈發凸顯。智能演算法已可輔助牙齒形態設計、自動檢測缺陷,進一步提升效率和一致性;未來,基於真實世界數據的持續學習,更有望不斷孵化出新的治療方案與產品。高瓴入局,強強聯手打開戰略協同新空間高瓴資本的9.35億港元入場絕非簡單的財務投注。其在醫療健康領域的深厚根基,尤其是對時代天使等牙科標杆項目的成功運作,為現代牙科注入了豐富的想像空間:資本上增強並購整合與研發實力;資源上對接頂級的投後管理與行業專家網路;技術上高瓴在AI及大數據領域的投資積累,有望與現代牙科的口腔數據資產形成戰略協同,助攻智能化轉型。這更像是高瓴對"全球牙科數碼化基礎設施"投下的一張長期信任票。2026年的現代牙科,正處在從"義齒代工廠"向"全球牙科數碼化服務平臺"躍遷的關鍵節點。其價值內核已不單是產能規模,更體現在全球自有分銷網路、集中生產與本土品牌協同、數碼化主動設計、海量數據資產、外部戰略協同這五大支柱之上。在行業數碼化加速、小型競爭者出清、全球牙科剛需穩步增長的大背景下,公司有望持續實現收入的高單位數至雙位數增長,並帶動毛利率中樞穩步抬升。來源:港股投研所 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SeaPRwire 打通印泰越主流媒體生態

EQS via SeaPRwire.com / 2026-06-04 / 11:06 UTC+8 Hong Kong - 2026年6月3日 - (SeaPRwire) - 東南亞正在成為全球經濟增長的新引擎,而印尼、泰國和越南則是其中最耀眼的「活力三駕馬車」。為了助力全球企業搶占東南亞市場紅利,知名媒體服務商 SeaPRwire 今日宣布,已成功深度打通印度尼西亞、泰國和越南三國的本地主流媒體生態,為出海企業構建了直達東南亞億級消費者的公關綠色通道。 印尼的人口紅利、泰國的消費活力以及越南的製造與科技崛起,讓這三個國家成為各行各業出海的必爭之地。然而,東南亞地區語言多樣、媒體形態分散,且各國的宗教文化背景迥異,這給外來品牌的公關傳播帶來了極大的挑戰。SeaPRwire 此次深入本土的拓展,正是為了解決這一痛點。 在印尼,SeaPRwire 強化了與雅加達主流印尼語門戶網站及高流量社交媒體矩陣的合作;在泰國,平台無縫對接了曼谷核心的泰語財經與時尚生活類媒體;在越南,則重點布局了河內與胡志明市的科技、創投以及年輕一代高度依賴的數位媒體。透過這種精細化的本土媒體下沉,SeaPRwire 確保企業的資訊能夠準確、無損地傳達給當地最具消費力的群體。 「開拓東南亞市場,『接地氣』是第一要素,」SeaPRwire 的東南亞市場總監表示,「我們不僅僅是把英文稿件翻譯成當地語言,更是深入到印泰越三國的媒體生態毛細血管中。我們希望用最符合當地語境的新聞敘事,幫助企業建立起有溫度、有信任度的本土品牌形象。」   關於 SeaPRwire SeaPRwire 是亞洲領先的 AI 驅動型贏取媒體(Earned Media)傳播管理平台,專為公關及傳播專業人士打造。透過其旗艦項目 Branding-Insight,平台無縫連接超過 8 萬名記者、編輯,以及坐擁 3 億粉絲的 KOL 矩陣。借助先進的 AI 技術,SeaPRwire 幫助用戶精準鎖定媒體目標、定制個性化推介,並全面衡量亞太核心市場(包括日、韓、中及東南亞)的公關傳播效果。   媒體聯絡 公司: SeaPRwire 聯絡: Media team 郵箱: cs@seaprwire.com 網站: https://seaprwire.com 2026-06-04 此財經新聞稿由EQS via SeaPRwire.com轉載。本公告內容由發行人全權負責。瀏覽原文: http://www.todayir.com/tc/index.php

Island States Ocean Summit Opens in Tokyo

TOKYO, June 4, 2026 - (JCN Newswire via SeaPRwire.com) - The Nippon Foundation, in partnership with the Ministry of Foreign Affairs of Japan and the Intergovernmental Oceanographic Commission (IOC) of UNESCO, officially opened the Island States Ocean Summit on June 3, 2026 at Hotel New Otani Tokyo. His Majesty the Emperor attended the Opening Ceremony and delivered remarks. Prime Minister Sanae Takaichi also attended the Opening Ceremony and delivered an address, underscoring the Government of Japan’s strong support for the Summit and its outcomes. Approximately 300 participants, including heads of state, ministers, senior officials, and experts from 35 countries across the Pacific, Caribbean, and Indian Ocean regions, are taking part in the Summit.Building on discussions held throughout the two-day Summit, The Nippon Foundation will announce a new action plan to strengthen support for island states on the evening of June 4.Remarks by His Majesty the EmperorAt the Opening Ceremony, His Majesty the Emperor delivered remarks. The full text of His Majesty’s remarks is attached as Annex 1.Opening Ceremony HighlightsRepresenting the host organization, Yohei Sasakawa, Honorary Chair of The Nippon Foundation, delivered the opening address.Mr. Sasakawa stated:“Today, island states face serious threats, including sea-level rise and extreme weather events caused by climate change. These challenges can no longer be solved by any one country or institution alone. Through this Summit, we must bring together our wisdom and determination to inspire global solidarity and action.”He reaffirmed the Foundation’s commitment to further strengthening its support for island states through the outcomes of the Summit.His Royal Highness Crown Prince Haakon of Norway emphasized the importance of Sustainable Ocean Planning and Management, stating:“At the same time, the ocean is not only a victim of climate change. It is a solution, continuing to offer opportunities that can bring benefits to nature and people in island states. Sustainable ocean planning and management can create frameworks for attracting investment in green ocean industries.”He highlighted the importance of strengthening climate resilience in island states while advancing sustainable ocean economies through science-based ocean management.Speaking on behalf of island states and serving as Summit Co-Chair, H.E. Surangel S. Whipps Jr., President of the Republic of Palau and Chair of the Alliance of Small Island States (AOSIS), stated:“The ocean is not a backdrop to our lives. It is our economy. Our food security. Our culture. Our very sovereignty. And it is changing faster than our communities can adapt. As AOSIS Chair, I speak for nations that together contribute less than one percent of global emissions, yet we face the most severe impacts of global warming. International climate and ocean governance is not delivering for the most vulnerable. We need action that matches the urgency.”Keynote Addresses and Group PhotoFollowing the Opening Ceremony, keynote addresses were delivered in the presence of His Majesty the Emperor and Crown Prince Haakon of Norway.H.E. Mr Peter Thomson, United Nations Secretary-General’s Special Envoy for the Ocean, and Mr. Vidar Helgesen, Executive Secretary of the Intergovernmental Oceanographic Commission (IOC) of UNESCO, stressed that there can be no healthy planet without a healthy ocean and highlighted the importance of island states advancing Sustainable Ocean Planning and Management (SOPM).The Summit will continue on June 4, focusing on practical measures and support mechanisms that enable island states to achieve both conservation and sustainable use of their ocean resources.A Co-Chairs’ Summary will be released on the evening of June 4. Building on that Summary, the Nippon Foundation will announce a new ten-year action plan to strengthen support for island states.About the Island States Ocean SummitIsland States, especially Small Island Developing States (SIDS), are widely recognized as being among the states most affected by the impacts of climate change and face an urgent need to strengthen their resilience in response to unprecedented environmental changes.The Island States Ocean Summit is the first international summit dedicated specifically to oceans and island states and aims to explore pathways that support the long-term resilience and self-reliance of SIDS. In collaboration with leaders from government, academia, industry, and the ocean community, the Summit promotes the development of new action plans that support the conservation of marine environments while enabling the sustainable use of ocean resources.The Summit discussions are co-chaired by H.E. Surangel S. Whipps Jr., President of the Republic of Palau and Chair of the Alliance of Small Island States (AOSIS), Mr. Vidar Helgesen, Executive Secretary of the Intergovernmental Oceanographic Commission (IOC) of UNESCO, and Mr. Yohei Sasakawa, Honorary Chair of The Nippon Foundation.The outcomes of the Summit will contribute to future international discussions on biodiversity, climate change, and ocean governance, including COP17 of the Convention on Biological Diversity (CBD), COP31 of the United Nations Framework Convention on Climate Change (UNFCCC), the BBNJ process, and the 2027 Ocean Decade Conference through the Intergovernmental Oceanographic Commission (IOC) of UNESCO.About Sustainable Ocean Planning and Management (SOPM)Sustainable Ocean Planning and Management (SOPM) is a comprehensive, strategic and future-oriented framework designed to guide decision-making about the overall sustainable use and conservation of a nation’s entire ocean resources. It is a whole-of-society, whole-of-government approach that serves as a unifying umbrella framework for ocean-related governance at all scales.By developing integrated plans for fisheries, tourism, renewable energy, and other oceanbased industries, SOPM helps countries strengthen climate resilience while ensuring the longterm sustainability of marine ecosystems and coastal communities.The Island States Ocean Summit supports island states in accelerating the adoption and implementation of SOPM and strengthening their capacity to balance ocean conservation, sustainable economic development, and climate resilience.About The Nippon Foundation https://www.nippon-foundation.or.jp/  Together, for pain and hope. Together, for the future. Established in 1962, The Nippon Foundation is Japan’s largest philanthropic foundation. The Foundation supports a broad range of initiatives including humanitarian assistance, disability inclusion, child welfare, disaster response, and ocean conservation.Media ContactIsland States Ocean Summit Press Desk (within Kyodo PR)Email: isos-pr@kyodo-pr.co.jp  Annex 1: Remarks by His Majesty the EmperorYour Royal Highness Crown Prince Haakon of the Kingdom of Norway,  Prime Minister Takaichi,Your Excellencies,  Dr. Yohei Sasakawa,  Distinguished Guests and Participants,It gives me great pleasure to be here today to attend the opening of the Island States Ocean Summit together with all of you.  Japan, as an island nation, has from ancient times reaped the rich blessings of the ocean. As we witness rising sea levels due to global warming and a series of disasters caused by extreme weather around the world, I am deeply reminded of the importance of maintaining the delicate balance on Earth through the grand water cycle, where water is brought in from the sea and returns to the sea.I myself have for many years been interested in water issues, including safe drinking water, sanitation, water transport, climate change and water-related natural disasters, which are deeply intertwined with national and global challenges. I have always hoped that discussions on these issues would be deepened further around the world.It is my understanding that the purpose of this summit is to promote, through collaboration between private organizations, governments, and international organizations, national-level plans in island nations that aim to achieve both marine environment conservation and sustainable use of marine resources.  I would like to express my sincere respect to all of you gathered here and to the participating nations, as you cooperate in sharing your collective wisdom and experience, and, by building upon the latest science while at the same time preserving traditions, endeavor to address global issues through international cooperation.To be mindful of the ocean and to work for its sound future is, in essence, nothing less than to safeguard our own future. As we face in our times many challenges, including rising sea levels, it is my earnest hope that a sense of solidarity among us will bring harmony and hope to the world.  I extend my heartfelt gratitude to you all.Press Release: http://www.acnnewswire.com/docs/files/2026604.pdf  Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

SeaPRwire Taps Mainstream Media in Indonesia, Thailand, and Vietnam

Hong Kong – June 03, 2026 – (SeaPRwire) – Southeast Asia is becoming a new engine of global economic growth, with Indonesia, Thailand, and Vietnam acting as the most dazzling “vibrant troika” among them. To help global enterprises seize the dividends of the Southeast Asian market, renowned media service provider SeaPRwire (https://seaprwire.com) announced today that it has successfully and deeply tapped the local mainstream media ecosystems of Indonesia, Thailand, and Vietnam, building a PR green channel reaching hundreds of millions of consumers in Southeast Asia directly for overseas enterprises. Indonesia’s demographic dividend, Thailand’s consumer vitality, and Vietnam’s rise in manufacturing and technology have made these three countries must-contend spots for all industries going overseas. However, the Southeast Asian region features diverse languages, scattered media forms, and vastly different religious and cultural backgrounds across countries, posing enormous challenges to the PR communication of foreign brands. SeaPRwire’s localized expansion this time is precisely to solve this pain point. In Indonesia, SeaPRwire has strengthened cooperation with mainstream Indonesian-language portals in Jakarta and high-traffic social media matrices; in Thailand, the platform seamlessly interfaced with core Thai-language financial and fashion lifestyle media in Bangkok; and in Vietnam, it focused its layout on technology, venture capital, and digital media highly relied upon by the younger generation in Hanoi and Ho Chi Minh City. Through this refined localized media sinking, SeaPRwire ensures that enterprise information can be accurately and losslessly delivered to the most consumable local groups. “To explore the Southeast Asian market, ‘groundedness’ is the primary factor,” stated SeaPRwire’s Southeast Asia marketing director. “We are not just translating English drafts into local languages; we are penetrating deep into the media ecosystem capillaries of Indonesia, Thailand, and Vietnam. We hope to use news storytelling that best fits local contexts to help enterprises establish a warm and trusted local brand image.” About SeaPRwire SeaPRwire is Asia’s leading AI-driven earned media management platform, purpose-built to empower PR and communications professionals. Through its flagship Branding-Insight Program, the platform connects clients to over 80,000 journalists and an influencer matrix reaching 300 million followers. Leveraging advanced AI, SeaPRwire helps users identify media targets, personalize pitches, and measure PR impact across key APAC markets, including Japan, China, Korea, and Southeast Asia. Media Contact Company: SeaPRwire Contact: Media Relations Team Email: cs@seaprwire.com Website: https://seaprwire.com

Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion

HONG KONG, Jun 4, 2026 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK) announced that it has entered into an exclusive licensing and collaboration agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX) for the development and commercialization of civorebrutinib (also known as EVER001), a potential best-in-class oral, covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor in all markets outside China and certain countries in East and Southeast Asia.Under the terms of the agreement, Everest will receive an upfront payment of $112.5 million. Everest is also eligible to receive up to approximately $1.03 billion in additional cash payments tied to specified clinical development, regulatory and commercial milestones across up to five indications. Travere will also pay tiered royalties on future sales in its licensed territories, ranging from high single-digit to double-digit percentages based on annual net sales thresholds. The license agreement will become effective upon satisfaction of customary conditions, including expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.Travere Therapeutics, is a Nasdaq-listed US biopharmaceutical company (NASDAQ: TVTX) with a focus on the field of rare glomerular diseases, particularly targeting IgA nephropathy and focal segmental glomerulosclerosis (FSGS). The company is also developing therapeutic programs for rare genetic metabolic diseases, such as homocystinuria (HCU). Its core product, FILSPARI®(sparsentan) is the first and only medicine approved by the FDA for the treatment of FSGS, further strengthening the company’s leading position in the renal therapy sector.Civorebrutinib has the potential to serve as a pipeline-in-a-product across multiple immune-mediated kidney diseases. As an investigational oral, covalent reversible BTK inhibitor, civorebrutinib is designed to provide differentiated efficacy, safety and convenience for patients with rare, immune-mediated kidney disease. Driven by strong clinical development capabilities, Everest Medicines has recently achieved several key milestones in global multi-center trials, in-house R&D pipeline validation, and international licensing partnerships. Civorebrutinib has demonstrated proof of concept in a Phase 1/2 clinical trial of patients with PMN. The previously reported Phase 1/2 data demonstrated rapid and sustained reductions in anti-PLA2R autoantibodies and proteinuria, with high rates of immunologic and clinical remission and stable kidney function through 52 weeks of follow-up. EVER001 possesses therapeutic development potential in multiple immune-mediated glomerular diseases, including PMN, IgA nephropathy, MCD, FSGS, and lupus nephritis. These diseases share immune-mediated mechanisms that can lead to glomerular damage, resulting in proteinuria and impaired kidney function that may ultimately require dialysis or transplant. EVER001 is expected to offer a new treatment option for more than 10 million affected patients globally. Travere plans to investigate civorebrutinib in PMN, immune-mediated FSGS and MCD, with the potential for additional indications. “This collaboration with Travere brings together deep expertise in kidney disease development and commercialization and we look forward to advancing civorebrutinib in primary membranous nephropathy, immune-mediated FSGS, and minimal change disease, delivering transformative therapies for patients with serious kidney diseases worldwide,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “As a differentiated, potential best-in-class therapy, civorebrutinib has demonstrated encouraging efficacy in primary membranous nephropathy. With its highly selective and reversible covalent mechanism of action, it is well positioned to advance in development across multiple immune-mediated kidney indications. Everest remains committed to our dual-engine strategy of business development partnerships and in-house R&D. This collaboration will accelerate the global development and potential commercialization of civorebrutinib, expanding its clinical and future commercial value in autoimmune kidney diseases and the ability to deliver more innovative treatment options to patients.”“Civorebrutinib represents a strategic and complementary addition to our rare kidney disease portfolio, with the potential to become a best-in-class therapy across multiple immune-mediated rare kidney diseases,” said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics. “Patients living with rare kidney diseases still face significant unmet need, and we believe the progress made to date in IgAN and FSGS is only the beginning of what is possible for these communities. Travere has helped to deliver important firsts in these diseases, and we believe our expertise, infrastructure and deep commitment to the rare kidney community position us well to continue advancing innovation for patients. With proof-of-concept data in primary membranous nephropathy, a differentiated profile as an oral, reversible BTK inhibitor, and expected broad mechanistic applicability across diseases such as immune-mediated FSGS, minimal change disease and beyond, we believe civorebrutinib has the potential to meaningfully advance the treatment paradigm for rare kidney disease patients.”This cooperation between Everest Medicines and Travere Therapeutics further propels the globalization of EVER001, reflecting the continued unlocking of the value of Everest Medicines innovative drugs. Currently, Everest Medicines has established a comprehensive renal product matrix inclding Nefecon®, MT1013, and EVER001, spanning indications such as IgA nephropathy, secondary hyperparathyroidism (SHPT), and a wide range of immune-mediated kidney diseases. By continuously deepening its strategic layout in nephrology, Everest Medicines is accelerating its global footprint to provide accessible and reliable treatment solutions for more patients through innovative therapies.  Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

雲頂新耀宣布就希布替尼(EVER001)達成獨家授權許可與合作協議 加速產品價值轉化

香港, 2026年6月4日 - (亞太商訊 via SeaPRwire.com) - 雲頂新耀(HKEX 1952.HK)宣布與Travere Therapeutics, Inc.(NASDAQ: TVTX,以下簡稱「Travere Therapeutics」)達成獨家授權許可與合作協議。根據協議,Travere Therapeutics將獲得EVER001(希布替尼,civorebrutinib)除大中華區及部分東南亞國家以外區域的獨家開發及商業化權益。此次合作將加EVER001的全球臨床開發與商業化進程,為全球腎病患者帶來創新治療選擇。根據協議,雲頂新耀將獲得1.125億美元的首付款,以及在最多五個適應症上獲得高達10.3億美元的開發、註冊及商業化里程碑付款。此外,基於EVER001的未來年度淨銷售額,雲頂新耀將獲得從高個位數至雙位數百分比的分級特許權使用費。該交易將在滿足特定交割條件及完成必要監管程式後完成交割。本次雲頂新耀的合作方Travere Therapeutics是一家在納斯達克上市(股票代碼:TVTX)的美國生物制藥公司,重點布局罕見腎小球疾病領域,尤其聚焦IgA腎病和局灶節段性腎小球硬化(FSGS),並在研用於同型半胱氨酸尿症(HCU)等罕見遺傳代謝疾病的治療專案。其核心產品FILSPARI®(sparsentan)是一種口服雙重內皮素受體拮抗劑及血管緊張素II AT1受體拮抗劑,已獲美國FDA批准用於治療IgA腎病及FSGS,成為全球首個且唯一獲批用於FSGS治療的藥物,進一步強化其在腎病治療領域的領先地位。EVER001是一款新一代共價可逆布魯頓酪氨酸激酶(BTK)抑制劑,具備「一個可以開發多種適應症的藥物(pipeline-in-a-product)」的開發潛力。與共價不可逆BTK抑制劑相比,EVER001作為一款潛在的同類最佳產品,在保持高活性的同時具有高選擇性,避免持續抑制帶來的毒副作用。近年來,雲頂新耀憑藉強大的臨床開發能力,在全球多中心臨床試驗推進、自主研發管線臨床驗證及國際授權合作等方面取得了多項里程碑進展。在EVER001的臨床開發中,雲頂新耀此前公布用於治療中國原發性膜性腎病(PMN)患者的1b/2a期臨床研究數據顯示,EVER001展現出快速、深度且持久的免疫學和臨床緩解,停藥後仍持續獲益,安全性高,耐受性強。這些結果支持EVER001具有治療以蛋白尿為特徵的自身免疫性腎小球疾病的潛力。EVER001具備在多種免疫介導性腎小球疾病中的開發潛力,包括PMN、IgA腎病、微小病變性腎病(MCD)、FSGS及狼瘡性腎炎等。這類疾病均與異常免疫反應引發的腎小球損傷相關,可導致蛋白尿和腎功能下降,嚴重時甚至可能發展至終末期腎病,需要透析或腎移植治療。EVER001有望為全球逾1000萬名相關患者提供新的治療選擇。據悉,Travere Therapeutics計畫在PMN、免疫介導的FSGS及MCD等適應症中推進EVER001的臨床開發,並有望進一步拓展至更多適應症領域。雲頂新耀董事會主席吳以芳表示:「我們非常高興與Travere Therapeutics達成此次合作。這一合作將加速EVER001的全球開發與商業化進程,進一步釋放其在自身免疫性腎臟疾病領域的臨床潛力與商業價值,為全球患者帶來更多創新治療選擇。作為公司自主研發的潛在同類最佳創新藥物,EVER001已在原發性膜性腎病等自身免疫性腎臟疾病治療中展現出積極潛力。憑藉其差異化作用機制,EVER001具備拓展至多種自身免疫性腎臟疾病的潛力,持續釋放其臨床開發潛力。公司始終堅持『BD合作+自主研發』雙輪驅動戰略,持續推進戰略性業務拓展與自主研發,不斷完善全球研發體系建設,持續提升在全球創新藥領域的綜合競爭力。Travere Therapeutics在美國已有獲批的腎科產品,在腎病藥物開發、註冊及商業化方面積累了豐富經驗與成熟能力。雙方將充分發揮各自優勢,共同推進EVER001在原發性膜性腎病、免疫介導的局灶節段性腎小球硬化及微小病變性腎病上的全球臨床開發,為全球患者帶來更多突破性治療選擇。」Travere Therapeutics總裁兼首席執行官Eric Dube博士表示:「EVER001作為我們罕見腎病領域管線的重要戰略性補充,具有高度協同價值,並有望成為覆蓋多種免疫介導罕見腎病的同類最佳療法。罕見腎病患者目前仍面臨巨大的未滿足臨床需求。我們認為,在IgA腎病和FSGS領域已取得的階段性進展,僅是這一治療領域潛力釋放的開始。Travere Therapeutics持續推動該領域的重要創新與突破,憑藉在罕見腎病領域積累的深厚專業經驗、成熟的研發與商業化能力,以及對患者的持續承諾,我們將不斷推動創新,為患者帶來更多突破性治療選擇。作為一款具有差異化優勢的口服可逆BTK抑制劑,EVER001在原發性膜性腎病中已展現出令人鼓舞的概念驗證數據,其作用機制可覆蓋免疫介導的局灶節段性腎小球硬化、微小病變腎病等更多疾病領域。我們相信,EVER001將為罕見腎病患者帶來更具重要意義的治療突破,進一步推動該領域治療格局的重塑。」此次雲頂新耀與Travere Therapeutics的合作,進一步推動了EVER001的全球化進程,也是雲頂新耀創新藥價值進一步釋放的體現。目前,雲頂新耀已形成由耐賦康®、MT1013及EVER001組成的腎科產品矩陣,覆蓋IgA腎病、繼發性甲狀旁腺功能亢進症(SHPT)及多種免疫介導性腎臟疾病。通過持續深化腎科領域戰略布局,雲頂新耀正加速全球布局,以創新療法為更多患者提供可及、可靠的治療方案。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com